Great to see a startup willing to explicitly state they are treating ageing itself as a disease
Developing medicines that potentially halt, slow or reverse the aging process
Genflow Biosciences plc is a UK based biotech company with R&D facilities in Belgium and a US office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs.
The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results.
Managed by an experienced team with decades of experience in the pharmaceutical and biotechnology sectors, the company is optimistic that development programs will continue at pace in the next 24 months.
Genflow Biosciences Executive Team
• Eric Leire, Founder and CEO
• Cedric Szpirer, Head of CMC
Genflow Biosciences Board Members
• Yassine Bendiabdallah, Chairman
• Eric Leire, Chief Executive Officer
• Guy Charles Fanneau de la Horie, Non-executive director
• Peter King-Lewis, Non-executive director
• Tamara Joseph, Non-executive director
Genflow Biosciences Scientific Advisory Board
• Eric Verdin
• Vera Gorbunova
• Matthew Hirschey
• Manlio Vinciguerra
Visit website: http://genflowbio.com/
Mentioned in this Resource
Genflow Biosciences Blog Posts
Other people at Genflow Biosciences
Genflow Biosciences News
Genflow's sirtuin gene therapy can make old liver young again
Longevity Technology - 29-Mar-2022
Currently exploring the SIRT6 potential with University of Rochester’s Aging Research CenterRead more...
Genflow IPO listing: the first longevity firm to debut on London Stock Exchange
Longevity Technology - 10-Jan-2022
Seeking funds to develop gene therapies that target ageing in humans and dogsRead more...
SIRT6 variant plays a major role in preventing the aging process
Longevity Technology - 17-Aug-2021
Novel gene therapies to prevent the accelerated aging processRead more...